Additionally, an acquired reduction in dystrophin has been found in patients with SAMs [45] and a class I major histocompatibility complex (MHC)-transgenic mouse model of SAMs [46]. This evidence concerns the gene DMD and short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.